

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/583,782	11/27/2006	Mark L. Boys	PC28082A	6061	
28523 PEIZER INC.	7590 11/26/200	98	EXAM	EXAMINER	
PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD GROTON, CT 06340			MCDOWEL	MCDOWELL, BRIAN E	
			ART UNIT	PAPER NUMBER	
			1624		
			NOTIFICATION DATE	DELIVERY MODE	
			11/26/2008	ELECTRONIC	

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

~IPGSGro@pfizer.com

# Application No. Applicant(s) 10/583,782 BOYS ET AL.

Office Action Summary	Examiner	Art Unit					
	BRIAN MCDOWELL	1624					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply	reals on the cover sheet with the c	orrespondence at	iuress				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D.  - Estimations of time may be available under the provisions of 37 CFR 1.15  - If NO period for reply is a specified above, the maximum statutory period in the property of the property is a pecified above, the maximum statutory period in the property in	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this of D (35 U.S.C. § 133).	•				
Status							
Responsive to communication(s) filed on							
2a) ☐ This action is FINAL. 2b) ☑ This action is non-final.							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) <u>1-15</u> is/are pending in the application.							
4a) Of the above claim(s) 14 and 15 is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) <u>1-12</u> is/are rejected.							
7) Claim(s) 13 is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examine	r.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
<ol><li>Certified copies of the priority documents have been received in Application No</li></ol>							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau	ı (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	Interview Summary     Paper No(s)/Mail D						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Arformation Disclosure Statement(s) (FTO/S5/08)  5) Notice of Informal Patent Application							
Paper No(s)/Mail Date 2/27/2007	6) Other:						

вем

#### DETAILED ACTION

#### Priority

This application receives the priority date of 10/14/2003, which is drawn to Provisional Application 60/510,870.

An action on the merits of claims 1-13 is presented herein.

Claims 14-15 are not considered due to non-statutory use claims and are withdrawn from consideration. Cancellation of these claims is recommended.

### Specification

The abstract of the disclosure is objected to because of the word "hydrido". This word is used inappropriately to define hydrogen. See 112<sup>2nd</sup> paragraph rejection below.

Correction is required. See MPEP \$ 608.01(b).

## Claim Objections

Claim 13 is objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should not depend on another multiple dependent claim.

See MPEP § 608.01(n). Accordingly, claim 13 has not been further treated on the merits.

Page 3

Application/Control Number: 10/583,782

Art Unit: 1624

## Claim Rejections - 35 USC § 112 (2nd Paragraph)

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In instant claim 1, applicant recites the limitation "wherein  $R^a$  and  $R^c$  are independently selected from the group consisting of hydrido".

Allwords.come describes "hydrido" in the following context:

## hydrido complex

noun

 (chemistry) a complex hydride, such as sodium borohydride, containing a hydride ligand bonded to a central atom

The term "hydrido" is derived from "hydride, (i.e., the negative ion of hydrogen). A person skilled in the art normally would associate this term with inorganic complexes. Applicant is advised to replace "hydrido" with the word "hydrogen" to clear up any ambiguity.

Claims 2-12 depend on claim 1 and are therefore rejected.

## Claim Rejections - 35 USC § 112 (1st Paragraph)

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Application/Control Number: 10/583,782

Art Unit: 1624

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for compounds of the elected invention that includes the limitation where X = O and S, does not reasonably provide enablement for any other moleties that applicant is claiming for this particular variable. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

Pursuant to In re Wands, 858 F.2d 731,737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), one considers the following factors to determine whether undue experimentation is required: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. Some experimentation is not fatal; the issue is whether the amount of experimentation is "undue"; see In re Vaeck, 20 USPQ2d 1438, 1444. Analysis is described below:

Art Unit: 1624

(A) Breadth of claims: The breadth of the claims encompass any of the tens of thousands of compounds represented by applicant's elected invention, thus the claims are very broad.

- (B) The nature of the invention: Substituted pyrazinone compounds for treating inflammatory diseases.
- (C) State of the Prior Art: Chemistry is unpredictable. See In Re Marzocchi and Horton 169 USPQ at 367 paragraph 3:

"Most non-chemists would probably be horrified if they were to learn how many attempted syntheses fail, and how inefficient research chemists are. The ratio of successful to unsuccessful chemical experiments in a normal research laboratory is far below unity, and synthetic research chemists, in the same way as most scientists, spend most of their time working out what went wrong, and why. Despite the many pitfalls lurking in organic synthesis, most organic chemistry textbooks and research articles do give the impression that organic reactions just proceed smoothly and that the total synthesis of complex natural products, for instance, is maybe a labor-intensive but otherwise undemanding task. In fact, most syntheses of structurally complex natural products are the result of several years of hard work by a team of chemists, with almost every step requiring careful optimization. The final synthesis usually looks quite different from that originally planned, because of unexpected difficulties encountered in the initially chosen synthetic sequence. Only the seasoned practitioner who has experienced for himself the many failures and frustrations which the development (sometimes even the repetition) of a synthesis usually implies will be able to appraise

Application/Control Number: 10/583,782

Art Unit: 1624

such work ......Chemists tend not to publish negative results, because these are, as opposed to positive results, never definite (and far too copious)" Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface.

In the instant application where X = O, applicant provides excellent direction and guidance in the specification in regard to synthesizing these particular compounds (i.e., pyrazinones). One of ordinary skill in the art could envision obtaining the sulfur derivatives (X = S) via treatment of the latter pyrazinone with a sulfur reagent such as Lawesson's reagent. However in reference to obtaining the substituted imino derivatives, applicant provides no guidance and one of ordinary skill would expect arduous experimentation in obtaining these compounds since imines are unstable under certain conditions.

- (D) Skill of those in the art: The level of skill in the art is high.
- (E) Level of predictability in the art: It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved," and physiological activity is generally considered to be an unpredictable factor. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).
- (F) Direction or Guidance: Little guidance or direction is provided by applicant in reference to making compounds embraced by the elected invention other than those where X = O and S.
- (G) Working Examples: The compound core depicted with specific substituents represent a narrow subgenus for which applicant has provided sufficient guidance to make and use; however, this disclosure is not sufficient to allow extrapolation of the

Application/Control Number: 10/583,782

Art Unit: 1624

limited examples to enable the scope of the compounds instantly claimed. Applicant has provided no working examples of any compounds where the compound of formula (1) did not contain the variables previously mentioned above in the present application.

Within the specification, "specific operative embodiments or examples of the invention must be set forth. Examples and description should be of sufficient scope as to justify the scope of the claims. *Markush* claims must be provided with support in the disclosure for each member of the *Markush* group. Where the constitution and formula of a chemical compound is stated only as a probability or speculation, the disclosure is not sufficient to support claims identifying the compound by such composition or formula." See MPEP 608.01(p).

(H) The quantity of experimentation needed: Since there are very limited working examples as described above, the amount of experimentation is expected to be high and burdensome. Applicant fails to provide guidance and supporting information for making the thousands of other compounds which are encompassed by the claims, therefore undue experimentation would be expected.

Due to the level of unpredictability in the art, the very limited guidance provided, and the lack of working examples, the applicant has shown lack of enablement. MPEP 2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright,

Application/Control Number: 10/583,782 Page 8

Art Unit: 1624

999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here.

#### Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on Monday-Thursday 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/James O. Wilson/

Supervisory Patent Examiner, Art Unit 1624